References
- Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the ‘high-hanging fruit’. Nat Rev Drug Discov. 2018;17:197–13. doi:https://doi.org/10.1038/nrd.2017.227.
- Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520. doi:https://doi.org/10.3389/fimmu.2014.00520.
- Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, Zhao Y, Kleijer M, Sandlie I, de Haas M, et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun. 2011;2:599. doi:https://doi.org/10.1038/ncomms1608.
- Liu L. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J Pharm Sci. 2015;104:1866–84. doi:https://doi.org/10.1002/jps.24444.
- Mimura Y, Katoh T, Saldova R, O’Flaherty R, Izumi T, Mimura-Kimura Y, Utsunomiya T, Mizukami Y, Yamamoto K, Matsumoto T, et al. Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy. Protein Cell. 2018;9:47–62. doi:https://doi.org/10.1007/s13238-017-0433-3.
- Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick C, Kubbies M, Klein C, Umana P, Mossner E. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng Des Sel. 2016;29:457–66. doi:https://doi.org/10.1093/protein/gzw040.
- Wang X, Mathieu M, Brezski RJ. IgG Fc engineering to modulate antibody effector functions. Protein Cell. 2018;9:63–73. doi:https://doi.org/10.1007/s13238-017-0473-8.
- Saunders KO. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front Immunol. 2019;10:1296. doi:https://doi.org/10.3389/fimmu.2019.01296.
- An Z, Forrest G, Moore R, Cukan M, Haytko P, Huang L, Vitelli S, Zhao JZ, Lu P, Hua J, et al. IgG2m4, an engineered antibody isotype with reduced Fc function. MAbs. 2009;1:572–79. doi:https://doi.org/10.4161/mabs.1.6.10185.
- Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER, Scallon B, Teplyakov A, Malia TJ, Strohl WR. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods. 2014;65:114–26. doi:https://doi.org/10.1016/j.ymeth.2013.06.035.
- Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daeron M. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113:3716–25. doi:https://doi.org/10.1182/blood-2008-09-179754.
- Lau C, Gunnarsen KS, Hoydahl LS, Andersen JT, Berntzen G, Pharo A, Lindstad JK, Ludviksen JK, Brekke OL, Barratt-Due A, et al. Chimeric anti-CD14 IGG2/4 Hybrid antibodies for therapeutic intervention in pig and human models of inflammation. J Immunol. 2013;191:4769–77. doi:https://doi.org/10.4049/jimmunol.1301653.
- Mueller JP, Giannoni MA, Hartman SL, Elliott EA, Squinto SP, Matis LA, Evans MJ. Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells. Mol Immunol. 1997;34:441–52. doi:https://doi.org/10.1016/S0161-5890(97)00042-4.
- Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25:1256–64. doi:https://doi.org/10.1038/nbt1344.
- Wong EK, Kavanagh D. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Transl Res. 2015;165:306–20. doi:https://doi.org/10.1016/j.trsl.2014.10.010.
- Dmytrijuk A, Robie-Suh K, Cohen MH, Rieves D, Weiss K, Pazdur R. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist. 2008;13:993–1000. doi:https://doi.org/10.1634/theoncologist.2008-0086.
- Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement system part II: role in immunity. Front Immunol. 2015;6:257. doi:https://doi.org/10.3389/fimmu.2015.00257.
- Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785–97. doi:https://doi.org/10.1038/ni.1923.
- Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol. 2013;190:3831–38. doi:https://doi.org/10.4049/jimmunol.1203487.
- Melis JP, Strumane K, Ruuls SR, Beurskens FJ, Schuurman J, Parren PW. Complement in therapy and disease: regulating the complement system with antibody-based therapeutics. Mol Immunol. 2015;67:117–30. doi:https://doi.org/10.1016/j.molimm.2015.01.028.
- Morgan BP, Harris CL. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov. 2015;14:857–77. doi:https://doi.org/10.1038/nrd4657.
- Ricklin D, Barratt-Due A, Mollnes TE. Complement in clinical medicine: clinical trials, case reports and therapy monitoring. Mol Immunol. 2017;89:10–21. doi:https://doi.org/10.1016/j.molimm.2017.05.013.
- Woodruff TM, Nandakumar KS, Tedesco F. Inhibiting the C5-C5a receptor axis. Mol Immunol. 2011;48:1631–42. doi:https://doi.org/10.1016/j.molimm.2011.04.014.
- Egge KH, Barratt-Due A, Nymo S, Lindstad JK, Pharo A, Lau C, Espevik T, Thorgersen EB, Mollnes TE. The anti-inflammatory effect of combined complement and CD14 inhibition is preserved during escalating bacterial load. Clin Exp Immunol. 2015;181:457–67. doi:https://doi.org/10.1111/cei.12645.
- Skjeflo EW, Sagatun C, Dybwik K, Aam S, Urving SH, Nunn MA, Fure H, Lau C, Brekke OL, Huber-Lang M, et al. Combined inhibition of complement and CD14 improved outcome in porcine polymicrobial sepsis. Crit Care. 2015;19:415. doi:https://doi.org/10.1186/s13054-015-1129-9.
- Baumann CL, Aspalter IM, Sharif O, Pichlmair A, Bluml S, Grebien F, Bruckner M, Pasierbek P, Aumayr K, Planyavsky M, et al. CD14 is a coreceptor of Toll-like receptors 7 and 9. J Exp Med. 2010;207:2689–701. doi:https://doi.org/10.1084/jem.20101111.
- Osterbye T, Funda DP, Fundova P, Mansson JE, Tlaskalova-Hogenova H, Buschard K. A subset of human pancreatic beta cells express functional CD14 receptors: a signaling pathway for beta cell-related glycolipids, sulfatide and beta-galactosylceramide. Diabetes Metab Res Rev. 2010;26:656–67. doi:https://doi.org/10.1002/dmrr.1134.
- Pugin J, Heumann ID, Tomasz A, Kravchenko VV, Akamatsu Y, Nishijima M, Glauser MP, Tobias PS, Ulevitch RJ. CD14 is a pattern recognition receptor. Immunity. 1994;1:509–16. doi:https://doi.org/10.1016/1074-7613(94)90093-0.
- Weber C, Muller C, Podszuweit A, Montino C, Vollmer J, Forsbach A. Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects). Immunology. 2012;136:64–77. doi:https://doi.org/10.1111/j.1365-2567.2012.03559.x.
- Chenevier-Gobeaux C, Borderie D, Weiss N, Mallet-Coste T, Claessens YE. Presepsin (sCD14-ST), an innate immune response marker in sepsis. Clin Chim Acta. 2015;450:97–103. doi:https://doi.org/10.1016/j.cca.2015.06.026.
- Huber-Lang M, Barratt-Due A, Pischke SE, Sandanger O, Nilsson PH, Nunn MA, Denk S, Gaus W, Espevik T, Mollnes TE. Double blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice. J Immunol. 2014;192:5324–31. doi:https://doi.org/10.4049/jimmunol.1400341.
- Mollnes TE, Brekke OL, Fung M, Fure H, Christiansen D, Bergseth G, Videm V, Lappegard KT, Kohl J, Lambris JD. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood. 2002;100:1869–77.
- Barratt-Due A, Pischke SE, Brekke OL, Thorgersen EB, Nielsen EW, Espevik T, Huber-Lang M, Mollnes TE. Bride and groom in systemic inflammation–the bells ring for complement and Toll in cooperation. Immunobiology. 2012;217:1047–56. doi:https://doi.org/10.1016/j.imbio.2012.07.019.
- Hallstensen RF, Bergseth G, Foss S, Jaeger S, Gedde-Dahl T, Holt J, Christiansen D, Lau C, Brekke OL, Armstrong E, et al. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology. 2015;220:452–59. doi:https://doi.org/10.1016/j.imbio.2014.11.003.
- Schroeder HW Jr., Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol. 2010;125:S41–52. doi:https://doi.org/10.1016/j.jaci.2009.09.046.
- Abes R, Teillaud JL. Impact of glycosylation on effector functions of therapeutic IgG. Pharmaceuticals (Basel). 2010;3:146–57. doi:https://doi.org/10.3390/ph3010146.
- Hamel PA, Klein MH, Dorrington KJ. The role of the VL- and VH-segments in the preferential reassociation of immunoglobulin subunits. Mol Immunol. 1986;23:503–10. doi:https://doi.org/10.1016/0161-5890(86)90113-6.
- Hamel PA, Klein MH, Smith-Gill SJ, Dorrington KJ. Relative noncovalent association constant between immunoglobulin H and L chains is unrelated to their expression or antigen-binding activity. J Immunol. 1987;139:3012–20.
- Hasegawa H. Aggregates, crystals, gels, and amyloids: intracellular and extracellular phenotypes at the crossroads of immunoglobulin physicochemical property and cell physiology. Int J Cell Biol. 2013;2013:604867. doi:https://doi.org/10.1155/2013/604867.
- Stoops J, Byrd S, Hasegawa H. Russell body inducing threshold depends on the variable domain sequences of individual human IgG clones and the cellular protein homeostasis. Biochim Biophys Acta. 2012;1823:1643–57. doi:https://doi.org/10.1016/j.bbamcr.2012.06.015.
- Berntzen G, Lunde E, Flobakk M, Andersen JT, Lauvrak V, Sandlie I. Prolonged and increased expression of soluble Fc receptors, IgG and a TCR-Ig fusion protein by transiently transfected adherent 293E cells. J Immunol Methods. 2005;298:93–104. doi:https://doi.org/10.1016/j.jim.2005.01.002.
- Norderhaug L, Olafsen T, Michaelsen TE, Sandlie I. Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells. J Immunol Methods. 1997;204:77–87. doi:https://doi.org/10.1016/S0022-1759(97)00034-3.
- Sela-Culang I, Kunik V, Ofran Y. The structural basis of antibody-antigen recognition. Front Immunol. 2013;4:302. doi:https://doi.org/10.3389/fimmu.2013.00302.
- Strohl WR. Current progress in innovative engineered antibodies. Protein Cell. 2018;9:86–120. doi:https://doi.org/10.1007/s13238-017-0457-8.
- Kamath AV. Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. Drug Discov Today Technol. 2016;21–22:75–83. doi:https://doi.org/10.1016/j.ddtec.2016.09.004.
- Barratt-Due A, Pischke SE, Nilsson PH, Espevik T, Mollnes TE. Dual inhibition of complement and Toll-like receptors as a novel approach to treat inflammatory diseases-C3 or C5 emerge together with CD14 as promising targets. J Leukoc Biol. 2017;101:193–204. doi:https://doi.org/10.1189/jlb.3VMR0316-132R.
- Ricklin D, Mastellos DC, Reis ES, Lambris JD. The renaissance of complement therapeutics. Nat Rev Nephrol. 2018;14:26–47. doi:https://doi.org/10.1038/nrneph.2017.156.
- Generics and Biosimilars Initiative. Epirus expands biosimilars pipeline with bioceros acquisition. Pro pharma communications international. October 2, 2015 online post. http://gabionline.net/layout/set/print/Pharma-News/Epirus-expands-biosimilars-pipeline-with-Bioceros-acquisition.
- Zheng K, Yarmarkovich M, Bantog C, Bayer R, Patapoff TW. Influence of glycosylation pattern on the molecular properties of monoclonal antibodies. MAbs. 2014;6:649–58. doi:https://doi.org/10.4161/mabs.28588.
- Li W, Zhu Z, Chen W, Feng Y, Dimitrov DS. Crystallizable fragment glycoengineering for therapeutic antibodies development. Front Immunol. 2017;8:1554. doi:https://doi.org/10.3389/fimmu.2017.01554.
- Wang Q, Chung CY, Chough S, Betenbaugh MJ. Antibody glycoengineering strategies in mammalian cells. Biotechnol Bioeng. 2018;115:1378–93. doi:https://doi.org/10.1002/bit.26567.
- Hailman E, Lichenstein HS, Wurfel MM, Miller DS, Johnson DA, Kelley M, Busse LA, Zukowski MM, Wright SD. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med. 1994;179:269–77. doi:https://doi.org/10.1084/jem.179.1.269.
- Niesen FH, Berglund H, Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc. 2007;2:2212–21. doi:https://doi.org/10.1038/nprot.2007.321.
- Bergseth G, Ludviksen JK, Kirschfink M, Giclas PC, Nilsson B, Mollnes TE. An international serum standard for application in assays to detect human complement activation products. Mol Immunol. 2013;56:232–39. doi:https://doi.org/10.1016/j.molimm.2013.05.221.
- Mollnes TE, Lea T, Harboe M, Tschopp J. Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. Scand J Immunol. 1985;22:183–95. doi:https://doi.org/10.1111/sji.1985.22.issue-2.